Introduction
============

Since the advent of assisted reproductive technology (ART), there has been continued effort to identify factors affecting embryo implantation which have an important bearing on the final treatment outcome. The inability to predict successful implantation even after transfer of "good quality" embryos in a normal uterus without any obvious intracavity pathology, can lead to disappointment for the couple and treating clinician.

One of the reasons for failure of implantation is due to an alteration in the implantation potential of the endometrium ([@B1]). A suggested cause is a premature progesterone elevation which causes endometrial advancement and impairs receptivity ([@B2]). Controlled ovarian stimulation with high dose exogenous gonadotropins does increase the oocyte yield but adversely affects the implantation potential of the endometrium ([@B3]).

It has been suggested that the decrease in the endometrial receptivity due to ovarian stimulation is due to an alteration in the protein profile expression ([@B4]). In addition, new metabolomics ([@B5]) and genomic ([@B6]) data have brought the possibility of predicting and thereby improving the implantation potential. Currently, such technologies are not widely used and also suffer from a lack of standardization ([@B7]). A rapid, reliable non-invasive test capable of predicting endometrial implantation could be an important tool which can help optimize the ART outcomes ([@B8]).

Premature elevated progesterone level during controlled ovarian stimulation has been associated with decreased endometrial receptivity ([@B2]). A prematurely elevated progesterone level advances the endometrial window of receptivity leading to an asynchrony between the endometrium and the embryo ([@B3]) which in turn leads to a failure of implantation ([@B9]). However, the literature has been conflicting due to factors such as discrepancies in cut-offs, heterogeneous patient characteristics and the different stimulation protocols used ([@B10]).

Varying cut-offs have been used to define an elevated progesterone during ART cycles, ranging from 0.8 to 2.0 *ng/ml* ([@B11]--[@B15]). However, recent studies have defined an elevation of serum progesterone using a cut-off of 1.5 *ng/ml* since there has been evidence of a marked difference in endometrial gene expression profiles above and below serum progesterone levels of 1.5 *ng/ml* ([@B16], [@B17]).

A premature progesterone elevation does not uniformly mean a failed implantation, because there are still clinical pregnancies recorded in cycles with high progesterone levels. Hence, there is a need to identify the subgroup of patients who have a good chance of conception in spite of elevated progesterone levels. One earlier study has suggested that there is a subgroup of high responders in whom elevated progesterone doesn\'t negatively affect the outcome ([@B18]).

Progesterone/Estradiol (P~4~/E~2~) ratio has been suggested as a marker for predicting clinical pregnancy rates, but the evidence is conflicting ([@B19]--[@B21]).

In this study, an attempt was made to evaluate the usefulness of P~4~/E~2~ ratio to predict implantation and clinical pregnancy in cycles with prematurely elevated progesterone during ART.

Methods
=======

A retrospective analysis of all ART cycles was done at the infertility unit of a tertiary care hospital from January 2011 to December 2012. During the study period, a total of 569 fresh embryo transfers were carried out. These included 289 antagonist cycles, 188 long protocol, 49 ultralong protocol and 43 short protocol cycles.

Cycle regulation before the IVF cycle was done using oral contraceptive pills. The choice of protocol and dose of recombinant gonadotropins was chosen according to the patient\'s age, BMI, antral follicle count and the indication for IVF.

For antagonist protocol, recombinant follicle stimulating hormone (rFSH) (Recagon, Organon pharmaceuticals, Dublin, Ireland) was started from the first or second day of menstrual cycle. Follicular monitoring was initiated from the 5th day of controlled ovarian hyperstimulation (COH) and antagonist (Ganirelix, Organon pharmaceuticals, Dublin, Ireland) was added at a dose of 0.25 *mg* subcutaneously once the lead follicle reached a size of 14 *mm* or more (multiple dose, flexible regime). Daily doses of antagonist were given till the day of human chorionic gonadotropin (hCG) trigger.

In case of long protocol, down regulation was achieved using leuprolide acetate (Lupride, Sun pharmaceuticals, Gujarat, India) at a dose of 0.5 *mg* subcutaneously daily starting from day 21 of the previous menstrual cycle till the day of hCG administration. Recombinant FSH was started from the first or second day of menstrual cycle and follicle monitoring by ultrasound was initiated from the sixth day of COH.

For ultralong protocol, which was used in cases of endometriosis undergoing ART, long-term pituitary down regulation was achieved by administering leuprolide acetate in monthly depot doses (3.75 *mg* intramuscularly) starting three months before the ART cycle. The down regulation was continued by using leuprolide acetate 0.5 *mg* subcutaneously daily till the day of hCG administration.

For anticipated poor responders, short protocol was used. Leuprolide acetate was started from the first day of menstrual cycle at a dose of 1 *mg* subcutaneously for initial three days (for the flare effect), and then, daily doses of 0.5 *mg* subcutaneously were continued daily till the day of hCG administration. Recombinant FSH was started from the third day of starting leuprolide acetate and follicle monitoring by ultrasound was initiated from the sixth day of stimulation.

Cycle monitoring was done using serial ultra-sound till the leading follicle cohort reached 18 *mm*, when triggering was done using Injection of hCG 5000 *IU* (Pregnyl, Organon pharmaceuticals, Dublin, Ireland).

Serum estradiol and progesterone levels were estimated on the day of hCG trigger using electro-chemiluminescence assay by Roche e411 ([@B22]) with an assay range for estradiol from 0.005 *ng/ml* to 4.3 *ng/ml* and for progesterone from 0.030 to 60.00 *ng/ml*.

Transvaginal ultrasound guided oocyte retrieval was scheduled 35 *hr* after hCG injection. The retrieved oocytes were incubated for 3--4 *hr* in fertilization medium, and then decision for IVF or ICSI was taken depending on the indication, the number of oocytes and previous fertilization rates. Short incubation insemination (2 *hr*) and group culture were followed for IVF. Oocyte denudation was done before ICSI. The oocytes were incubated overnight in mini incubator with triple gas mixture and observed 16--18 *hr* post insemination/ injection for fertilization. Embryo transfer was done at the cleavage or blastocyst stage using Sydney IVF (SIVF) catheters. Luteal support was given with vaginal micronized progesterone pessaries 400 *mg* twice daily post-oocyte retrieval and intramuscular progesterone 100 *mg* twice weekly.

Pregnancy was confirmed by taking a positive serum beta hCG 14 days after embryo transfer. Transvaginal ultrasound was done two weeks after a positive serum beta hCG and a clinical pregnancy was defined as the ultrasonographic visualization of one or more gestational sacs ([@B23]).

Statistical analysis was done using SPSS version 17.0 ([@B24]) using Fischer\'s exact test for 2×2 contingency table taking a p-value of \<0.05 as significant.

Results
=======

A total of 569 fresh embryo transfer cycles were carried out during the study period. Thirty six cycles had a premature progesterone (P~4~) elevation with a level \>1.5 *ng/ml* on the day of hCG. The baseline clinical characteristics of age and BMI were not significantly different between the elevated progesterone and the normal progesterone group ([Table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics

                                                         **Progesterone \>1.5 *ng.ml***   **Progesterone ≤1.5 *ng/ml***   **p-value**
  ------------------------------------------------------ -------------------------------- ------------------------------- -------------
  **Age (years) [\*](#TFN1){ref-type="table-fn"}**       31.5±4.9                         31.7±4.4                        0.804
  **BMI (*kg/m*^2^) [\*](#TFN1){ref-type="table-fn"}**   23.3±4.9                         25.2±4.1                        0.06

M±SD

There were 244 clinical pregnancies from 569 fresh embryo transfer cycles, with a clinical pregnancy rate per embryo transfer of 42.8% among all cycles.

Among the 533 fresh embryo transfer cycles with progesterone level ≤1.5 *ng/ml*, there were 236 clinical pregnancies giving a clinical pregnancy rate of 44.2%. Among the 36 fresh embryo transfer cycles with progesterone level \>1.5 *ng/ml*, there were eight clinical pregnancies giving a clinical pregnancy rate of 22.2% ([Table 2](#T2){ref-type="table"}).

###### 

Clinical pregnancy rate in all ART cycles

                        **Number of cycles**   **Clinical pregnancies**   **Clinical pregnancy rate**   **p-value**
  --------------------- ---------------------- -------------------------- ----------------------------- -------------
  **All cycles**        569                    244                        42.8%                         
  **P ≤1.5 *ng/ml***    533                    236                        44.2%                         0.0092
  **P \>1.5 *ng/ml***   36                     8                          22.2%                         

Subgroup analysis was done within the cycles with elevated progesterone (\>1.5 *ng/ml*). Out of 36 cycles, 20 cycles had a progesterone/estradiol (P~4~/E~2~) ratio of \>1 and 16 cycles had a P~4~/E~2~ ratio of ≤1. Of the 20 cycles, with P~4~/E~2~\>1, there were only 3 clinical pregnancies with a clinical pregnancy rate per embryo transfer of 15%. And of the 16 cycles with P~4~/E~2~ ≤1, there were 5 clinical pregnancies with a clinical pregnancy rate of 31.3% ([Table 3](#T3){ref-type="table"}).

###### 

Clinical pregnancy rate-subgroup analysis

                                                      **Number of cycles**   **Clinical pregnancies**   **Clinical pregnancy rate**   **p-value**
  --------------------------------------------------- ---------------------- -------------------------- ----------------------------- --------------------------------
  **P ≤1.5 *ng/ml* (Group 1)**                        533                    236                        44.2%                         0.0103 (Group 1 *vs*. Group 2)
  **P \>1.5 *ng/ml* and P~4~/E~*2*~ \>1 (Group 2)**   20                     3                          15%                           
  **P \>1.5 *ng/ml* and P~4~/E~*2*~ ≤1 (Group 3)**    16                     5                          31.3%                         0.4442 (Group 1 *vs*. Group 3)

Subgroup analysis was done for antagonist and long protocol cycles because only these cycles had sufficient numbers for a statistical analysis. Out of 289 antagonist cycles, 136 had a clinical pregnancy with a clinical pregnancy rate of 47.1%. The group with elevated progesterone \>1.5 *ng/ml* had a significantly lower clinical pregnancy rate of 17.6% (3/17) when compared to the group with progesterone ≤1.5 *ng/ml* where a clinical pregnancy rate of 48.9% (133/272) was obtained ([Table 4](#T4){ref-type="table"}).

###### 

Subgroup analysis of antagonist cycles

                         **Number of cycles**   **Clinical pregnancies**   **Clinical pregnancy rate**   **p-value**
  ---------------------- ---------------------- -------------------------- ----------------------------- -------------
  **All cycles**         289                    136                        47.1%                         \--
  **P ≤1.5 *ng/ml***     272                    133                        48.9%                         0.013
  **P \> 1.5 *ng/ml***   17                     3                          17.6%                         

There were a total of 188 long protocol cycles and a clinical pregnancy rate of 43.6% (82/188) was recorded. The group with elevated progesterone (\>1.5 *ng/ml*) had a lower clinical pregnancy rate of 28.5% (2/7) compared to the group with progesterone ≤1.5 *ng/ml*, which had a clinical pregnancy rate of 44.1% (80/181), but the difference did not reach statistical significance ([Table 5](#T5){ref-type="table"}).

###### 

Subgroup analysis of long protocol cycles

                         **Number of cycles**   **Clinical pregnancies**   **Clinical pregnancy rate**   **p-value**
  ---------------------- ---------------------- -------------------------- ----------------------------- -------------
  **All cycles**         188                    82                         43.6%                         \--
  **P ≤1.5 *ng/ml***     181                    80                         44.1%                         0.47
  **P \> 1.5 *ng/ml***   7                      2                          28.5%                         

Discussion
==========

In our study, progesterone elevation on the day of hCG trigger was associated with a significant reduction in clinical pregnancy rate (44.2% *vs*. 22.2%; p=0.0092). In the subgroup analysis of the patients with progesterone elevation, the group with P~4~/E~2~ \>1 showed a significant decrease in the pregnancy rate (44.2% *vs*. 15%; p=0.0103). Importantly, in the group with p\>1.5 *ng/ml* but P~4~/E~2~ ≤1, the pregnancy rate was similar to the group with normal progesterone level (44.2% *vs*. 31.3%; p=0.44).

The two mechanisms by which a premature progesterone surge can affect the ART outcome adversely is by having a deleterious effect either on the endometrium or the embryo. Elevated progesterone level has been implicated in accelerating the endometrial maturation leading to asynchrony between the endometrium and the developing embryo. Pregnancy is unlikely with asynchrony ≥3 days between expected and actual histological dating by Noyes\' criteria ([@B25]). Endometrium with a discrepancy of 3 days express separate molecular cluster profiles and different gene expressions ([@B16], [@B17], [@B26]). Progesterone elevation does not have deleterious effect on embryo quality as evidenced by studies in donor-oocyte programs ([@B13], [@B27], [@B28]).

The effect of elevated progesterone on ART outcome has been controversial with some studies stating that there is no negative impact of an elevated progesterone on pregnancy rates ([@B11]--[@B13], [@B15], [@B29]--[@B31]). The recent studies ([@B14], [@B32]--[@B35]), however, show that a premature elevation of progesterone does decrease pregnancy rates. A meta-analysis in 2007 (which included five studies, n=700 patients) ([@B36]) stated that the negative effect of progesterone on pregnancy outcome did not reach statistical significance. However, two subsequent meta-analyses by the same group, the first of which included only antagonist cycles (five studies, n=585 patients) ([@B37]) and another which evaluated 63 studies (n=55199 patients) ([@B38]) came to the conclusion that progesterone elevation significantly reduced the clinical pregnancy rates in fresh embryo transfer cycles.

Among the antagonist cycles, there was a significant lowering of the clinical pregnancy rate with a P~4~ level of \>1.5 *ng/ml* (p=0.013) which concurs with most previous studies ([@B32], [@B33], [@B39]). With regard to long protocol cycles, the difference in clinical pregnancy rates between the normal and elevated progesterone groups did not reach statistical significance (p=0.47) which is in agreement with previous studies ([@B11]--[@B13], [@B15], [@B29], [@B30], [@B40]).

A meta-analysis by Griesinger et al. ([@B18]) manifested that a premature progesterone elevation does not affect clinical pregnancy rates in high responders.

Progesterone/Estradiol was introduced as a novel marker by Younis et al. in 1998 ([@B41]) and it was calculated as progesterone (*ng/ml*)×1,000/estradiol (*pg/ml*). In this initial study ([@B41]) on superovulation and IUI cycles and in a later study ([@B42]) in ART cycles with the same group, the authors had put forth the hypothesis that a premature luteinisation defined as P~4~/E~2~ ratio \>1 was associated with a significantly reduced pregnancy rate. They also concluded that premature luteinisation and elevated P~4~/E~2~ ratio are associated with dysmature follicles in poor ovarian reserve patients. The same cut-off was used for this study, but with a change of units as P~4~/E~2~ ratio equals progesterone (*ng/ml*) /estradiol (*ng/ml*). A subsequent study ([@B19]) concluded that P~4~/E~2~ ratio was a better predictor than serum progesterone alone for prediction of clinical pregnancy. As regarding the subgroup of normo-responders undergoing ART, there is contradictory evidence ([@B20], [@B21]) as to whether elevated P~4~/E~2~ ratio has any impact on clinical pregnancy rate. A study in high responders ([@B43]) concluded that P~4~/E~2~ ratio is a more reasonable marker to predict pregnancy rate than serum progesterone alone, but P~4~/E~2~ ratio has low sensitivity and positive predictive value to predict pregnancy rates.

In our present study, among the cycles with a premature progesterone elevation (\>1.5 *ng/ml*), the subgroup of cycles with an elevated P~4~/E~2~ ratio of \>1 had a poorer outcome. In the other subgroup with a P~4~/E~2~ ratio of ≤1, the clinical pregnancy rates did not significantly differ from the cycles with a normal progesterone level of ≤1.5 *ng/ml*. Hence, the deleterious effect of progesterone elevation is possibly confined to only those cycles which have an elevated P~4~/E~2~ ratio as well. In clinical practice, a policy of cryopreservation of all embryos can be selectively considered for those ART cycles with P~4~ \>1.5 *ng/ml* and P~4~/E~2~ \>1. The subgroup with progesterone elevation but P~4~/E~2~ ≤1 can be expected to have a similar pregnancy outcome as those with progesterone ≤1.5 *ng/ml*. However, given the limited sample size of our study, our results need to be validated in further studies with larger sample size. For the same reason, comparison between our study and previous studies is also limited by the sample size.

One possibility could be that the endometrial advancement is not dependent on progesterone levels alone but by the relative levels of both estrogen and progesterone in the circulation ([@B44]).

The second reason could be that the progesterone elevation in P~4~/E~2~ ratio \>1 sub-group is the result of a subtle LH elevation due to inadequate pituitary desensitization and the cause in the group with P~4~/E~2~ ≤1 is due to a combination of a high number of follicles and a supraphysiological FSH drive ([@B45]). This disparity in the clinical pregnancy rates with the two groups of P~4~/E~2~ ratio could also explain why previous studies have shown that clinical pregnancy rates in high responders are not affected by a premature progesterone rise ([@B18]). High responders would be expected to have high estradiol levels and hence the elevation in progesterone would possibly be compensated by a P~4~/E~2~ ratio of ≤1. The third possibility could be that the progesterone elevation in P~4~/E~2~ ≤1 is due to a "physiological" secretion by multiple follicles, and the progesterone elevation in P~4~/E~2~ \>1 group is due to "premature luteinization" by dysmature follicles or in those with a low ovarian reserve ([@B21], [@B41], [@B42]).

Our current study had a retrospective design. The numbers of cycles with a progesterone level of ≥1.5 *ng/ml* are low, hence limiting the power of our statistical analyses. In addition, the stimulation strategies and doses were tailored to individual patients and hence were not uniform. This is a further limitation to our present study. Hence, our finding needs to be validated in a study with a prospective study design and with a larger sample size.

Conclusion
==========

To conclude, our findings suggest that a premature progesterone elevation in ART cycles is possibly associated with lower clinical pregnancy rates. However, this adverse impact of elevated progesterone seems to be limited mainly to a subgroup with an elevated P~4~/E~2~ ratio. This hypothesis needs validation in larger trials. Elective cryo-preservation of embryos is an option that needs to be discussed with this subgroup of patients.
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